MBX Biosciences, Inc. 8-K

What Happened
MBX Biosciences announced completion of an End-of-Phase 2 (EOP2) meeting with the U.S. FDA and plans to advance once-weekly canvuparatide into a pivotal Phase 3 trial for chronic hypoparathyroidism (HP), targeting initiation in Q3 2026. The company issued a press release on March 9, 2026 (attached as Exhibit 99.1 to the Form 8-K) and also disclosed that the European Medicines Agency has granted Orphan Drug Designation for canvuparatide for chronic HP.

Key Details

• Planned Phase 3 design: double-blind, placebo-controlled trial enrolling ~160 patients randomized 3:1 (approximately 120 on canvuparatide, 40 on placebo).
• Dosing and schedule: 4-week fixed dose at 600 ug once-weekly, followed by an 18-week dose-titration period and a 4-week maintenance period.
• Primary endpoint: proportion of participants who achieve normal serum calcium and independence from conventional therapy, assessed at Week 26; trial to be followed by an open-label extension.
• Regulatory milestone: EMA granted Orphan Drug Designation for once-weekly canvuparatide for chronic HP.

Why It Matters
This filing signals MBX moving its lead candidate into a registrational Phase 3 study and establishes a near-term development timeline (planned start in Q3 2026). The Phase 3 design, key endpoints and the EMA orphan designation are material to investors because they affect regulatory strategy, potential development incentives in Europe, and the path toward possible approval if trial results are positive. The filing also reiterates forward-looking risks noted by the company, including development, regulatory, manufacturing, third-party dependence and financing risks that could affect timelines and outcomes.